Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Medtronic
Boehringer Ingelheim
Merck
McKesson

Last Updated: August 19, 2022

Investigational Drug Information for AG-348


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug AG-348?

AG-348 is an investigational drug.

There have been 19 clinical trials for AG-348. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2021.

The most common disease conditions in clinical trials are Pyruvate Metabolism, Inborn Errors, Anemia, Hemolytic, Congenital Nonspherocytic, and Anemia, Hemolytic. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI), and National Institutes of Health Clinical Center (CC).

There are nine US patents protecting this investigational drug and one hundred and twenty-seven international patents.

Recent Clinical Trials for AG-348
TitleSponsorPhase
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodAgios Pharmaceuticals, Inc.Phase 3
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodAgios Pharmaceuticals, Inc.Phase 3
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell DiseaseAgios Pharmaceuticals, Inc.Phase 2/Phase 3

See all AG-348 clinical trials

Clinical Trial Summary for AG-348

Top disease conditions for AG-348
Top clinical trial sponsors for AG-348

See all AG-348 clinical trials

US Patents for AG-348

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AG-348 See Plans and Pricing Therapeutic compounds and compositions Agios Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
AG-348 See Plans and Pricing Pyruvate kinase activators for use in therapy Agios Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
AG-348 See Plans and Pricing Methods of using pyruvate kinase activators Agios Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
AG-348 See Plans and Pricing Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfon- amide Agios Pharmaceuticals, Inc. (Cambridge, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AG-348

Drugname Country Document Number Estimated Expiration Related US Patent
AG-348 Argentina AR077292 2029-06-29 See Plans and Pricing
AG-348 Argentina AR112803 2029-06-29 See Plans and Pricing
AG-348 Australia AU2010266386 2029-06-29 See Plans and Pricing
AG-348 Brazil BRPI1011587 2029-06-29 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Medtronic
Boehringer Ingelheim
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.